How to Localize Labels and Instructions for Overseas Registration of Imaging Devices?

In overseas registration of imaging devices, localizing labels and instructions for use (IFU) is not a simple translation task. It is a compliance exercise that must satisfy the target country's medical device regulations, language requirements, and clinical usage practices. Manufacturers must first determine whether the product falls under the target country's regulatory scope, then identify the applicable technical documentation, labeling requirements, and verification expectations based on risk classification and registration pathway. Most GHWP member states and markets in Southeast Asia and Latin America accept ISO 13485 certificates and test reports originating from NMPA, CE, or FDA submissions. However, labels and IFUs must be re-developed or converted—adopting local languages, adapting units of measurement, using recognized warning symbols, and ensuring strict consistency with the registration certificate. In addition, nearly all countries require a local agent or authorized representative to submit applications, interface with regulators, receive adverse event reports, and manage post-market changes. Common risks include direct machine translation leading to semantic errors or regulatory omissions, neglecting independent local clinical evaluation requirements, inconsistency between labels and supporting documents, and failure to update IFU versions after registration. Companies should conduct a regulatory gap analysis early in the project, establish a localization checklist, and preserve an evidence chain for renewals and changes.

Key Summary

For overseas registration of imaging devices, label and IFU localization must comply with target-country medical device regulations, language requirements, and clinical usage habits. Companies should first confirm whether the product is within the target country's regulatory scope, then determine the applicable technical files, labeling, and verification requirements based on risk class and registration pathway. Most GHWP members and Southeast Asian and Latin American markets accept ISO 13485 quality systems and test reports from NMPA, CE, or FDA submissions, but labels and IFUs must be re-created or converted—using local languages, adapting local units, adopting standardized warning symbols, and ensuring full alignment with the registration certificate. Nearly all countries also require a local agent or authorized representative to file applications, accept regulatory oversight, receive adverse event reports, and manage changes. Common risks include raw machine translation, missing local clinical evaluation independence, label/document inconsistency, and failure to update IFU versions after registration. A regulatory gap analysis, a localization checklist, and a retained evidence chain for renewal and change are essential.

Applicable Scenarios and Core Issues

Label and IFU localization for imaging devices is a compliance task that spans the entire product life cycle. Labels are affixed to the device or included in the smallest sales unit, while the IFU provides complete operating, maintenance, and clinical use instructions. Together, they are the primary tools for users to understand product risks, functions, and contraindications.

Imaging devices are among the most technically complex and strictly regulated medical device categories. During overseas registration, labels and IFUs, as part of the submission documents, are key review points for regulatory authorities and the basis for safe and correct use.

The core issue is not word-for-word translation, but ensuring that labels and IFUs fully comply with the target country's legal framework, language, units of measure, electrical safety symbols, risk management requirements, and the latest regulatory expectations regarding indications, contraindications, and clinical information. If a company simply sends the Chinese IFU to a translation agency, the content may be legally invalid.

This article is intended for imaging device manufacturers planning to enter GHWP member states and markets in Southeast Asia, the Middle East, and Latin America, outlining the decision logic, document preparation, and execution path for label and IFU localization.

Registration Decision Logic

When an export opportunity arises, the first step is to determine whether the product falls under the target country's medical device regulatory scope. Most countries classify medical imaging devices as Class II or Class III. However, some markets have different boundary rules for software functions, accessories, and low-risk products; each must be verified against local regulations.

Second, determine the registration pathway and applicant entity corresponding to the risk class. GHWP members generally operate a risk-based registration system. Companies usually need to appoint a local agent or authorized representative to submit the application in that entity's name and assume post-market responsibilities.

Third, evaluate the reusability of existing NMPA, CE, FDA, or other market registration files. ISO 13485 certificates, IEC 60601 series test reports, risk management files, and clinical evaluation reports are often directly acceptable. However, labels and IFUs must be localized and cannot be a direct copy of the Chinese version.

Finally, confirm whether the target market requires additional clinical evidence. Imaging devices in high-risk markets often require local clinical trials or acceptance of overseas clinical data. Before localizing the IFU, ensure the indication wording exactly matches the clinical evidence scope in the submission.

For companies applying in multiple GHWP member states simultaneously, a parameterized multilingual label template can significantly reduce redundant effort, but each country must still independently review its local regulatory differences.

Materials and Evidence

Base materials for localized labels and IFUs include the Chinese registration certificate, Chinese IFU, environmental and operating parameters from technical documentation, hazard warnings from the risk management report, and the label sample from the country of origin.

Most technical data and test reports can be reused. However, language, units, warnings, graphics, and symbols must be localized. Some target countries do not accept pinyin abbreviations and require local script; others require labels bearing the local agent's address and telephone number.

Electrical safety information in the IFU must be adjusted according to the local edition of IEC 60601-1 and any national deviations. Supply voltage, frequency, earthing, and protection class may differ materially between Chinese and English versions; simple word substitution is insufficient.

If clinical evaluation uses overseas data, verify that the target market accepts it, and supplement with local literature or rationale if needed. In the localized IFU, indications, contraindications, and clinical observations must strictly correspond to the clinical evidence submitted in the registration dossier.

Common Errors

Based on our experience with imaging device localization projects, the following high-frequency errors are observed:

• Using raw machine translation without regulatory review or clinical content validation, causing important warnings to be mistranslated or omitted.
• Ignoring local language requirements—for example, some countries require several official languages to appear simultaneously, or separate submissions for different language versions.
• Copying CE marks and FDA symbols without replacing them with target-country-recognized symbols and statements; some markets do not accept English warning signs.
• Inconsistencies between the manufacturer name, address, or agent information on the label and the registration certificate, triggering requests for correction during review.
• Failure to establish a localization change control process, so post-market IFU updates are not filed with the regulator through the local agent.

Company Preparation Checklist

The following checklist helps companies advance label and IFU localization step by step and avoid missing critical elements:

• Conduct a target-country regulatory gap analysis at project start, clarifying product classification, registration pathway, and specific label/IFU rules.
• Assemble a localization team with regulatory, clinical, testing, and translation expertise, or engage a localization service provider with medical device background.
• Develop multilingual label and IFU templates with field-based management for essential information such as product name, model, and warnings.
• Sign a contract with the local agent confirming responsibility for filing the registration and subsequent changes, and clarify how the agent's information appears on the label.
• After completing localized versions, have in-country professionals verify regulatory compliance and clinical appropriateness.
• Maintain version records, translation declarations, and proofreading logs for post-market regulatory evidence.

AIMEILI Regulatory Interpretation and Business Impact

AIMEILI believes the most common misjudgment in overseas registration of imaging devices is treating localization as a translation task. Many companies hand the Chinese IFU to a translation agency without addressing regulatory compliance, only to be asked to resubmit during review, causing delays and added cost.

At the project planning stage, first conduct a regulatory gap analysis for the target market. Create a checklist of mandatory rules for label/IFU format, language, symbols, product name, and agent information, then decide on internal staffing and external suppliers.

Core technical documents and technical data can be reused, but labels and IFUs must be re-localized. A translation agency solves language issues only; it does not address regulatory requirements. Companies must involve experts with medical device backgrounds in review.

The local agent is not a mere mailing address. The agent is responsible for submitting applications, hosting inspections, reporting adverse events, and handling changes. Companies should integrate the agent into the localization process and ensure the agent's information on the label is accurate and valid.

For multi-country registration, establishing multilingual templates and version control from the outset allows simultaneous updates to all market documents after changes, reducing duplication and remediation risk. Control of certificates should remain with the company to avoid expiration due to agent changes.

Frequently Asked Questions

Can English IFUs be used if the target country has no local language requirement?

Some countries accept English IFUs, but you must first confirm whether the regulatory authority requires an official language version. Even if English is accepted, include local agent information on the label and use international symbols. Do not assume based on incomplete information.

Is translation certification required for localized IFUs?

Most GHWP member states do not mandate notarized translations, but they require the manufacturer to be responsible for translation accuracy. Retain a translation declaration, proofreading records, and a cross-reference to the original technical file to provide during review if requested.

If the registration certificate changes, does the IFU need to be updated?

Yes. For example, if the product name, registrant, agent, or address on the registration certificate changes, a change application must be submitted through the local agent to the regulatory authority, and the labels and IFUs sold in that market must be updated simultaneously. Otherwise, the product may be deemed non-compliant after market entry.

Note: This article was compiled based on AIMEILI's registration practice database, the international medical device registration knowledge base, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and product-specific documentation.

Content author: AIMEILI Regulatory Editorial Department; Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: Priority is given to official regulatory authorities, international organizations, standards bodies, and public regulatory materials; industry media and project experience are used as supplementary references. Applicability boundary: This article is for preliminary understanding, document preparation, and project planning, and does not replace formal requirements from target-country regulators, testing conclusions, or legal advice.